Clinical Trial Update: Phase 1/2 Study of Chlamydia Trachomatis mRNA Vaccine in Adults Aged 18 to 29 Years [Phase 1, Phase 2]

View source ↗

Summary

Sanofi is conducting a Phase 1/2 clinical trial to evaluate an mRNA vaccine against Chlamydia trachomatis in adults aged 18 to 29; the study is currently recrui…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chlamydia Trachomatis Infection

Drugs mentioned

• Chlamydia trachomatis mRNA vaccine (Chlamydia trachomatis mRNA vaccine)

Snippet

Sponsor: Sanofi | Conditions: Chlamydia Trachomatis Immunization | Phase 1, Phase 2 | Status: RECRUITING